Analysis

Trump's Latest Drug Pricing Executive Order Draws Doubts

Law360 (September 14, 2020, 7:13 PM EDT) -- The executive order President Donald Trump announced Sunday that aims to sharply cut drug prices by capping prices of Medicare Part B and Part D drugs is unlikely to have any practical impact on consumers' wallets and underscores the limits of executive action, experts say.

Trump's order directs the U.S. Department of Health and Human Services to ensure that patients receiving drugs under Medicare Part B and Part D aren't paying more than non-U.S. purchasers in an economically comparable country within the Organization for Economic Cooperation and Development. Medicare Part B is insurance that pays for doctors' services while Part D...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!